Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 2716 AL 2730

Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review

Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.

CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.

Current Status of Alzheimer's Disease and Pathological Mechanisms Investigating the Therapeutic Molecular Targets

Bagga S, Kumar M.

Curr Mol Med. 2023;23(6):492-508. doi: 10.2174/1566524022666220404112843.

The Lymphatic System In The Brain Clearance Mechanisms - New Therapeutic Perspectives For Alzheimer's Disease

Chachaj A, Gąsiorowski K, Szuba A, Sieradzki A, Leszek J.

Curr Neuropharmacol. 2023;21(2):380-391. doi: 10.2174/1570159X20666220411091332.

Dopaminergic Signaling as a Plausible Modulator of Astrocytic Toll-Like Receptor 4: A Crosstalk between Neuroinflammation and Cognition

Gurram PC, Manandhar S, Satarker S, Mudgal J, Arora D, Nampoothiri M.

CNS Neurol Disord Drug Targets. 2023;22(4):539-557. doi: 10.2174/1871527321666220413090541.

The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease

Wang Y.

CNS Neurol Disord Drug Targets. 2023;22(4):577-598. doi: 10.2174/1871527321666220417005115.

Therapeutic Effects of Thymoquinone on Alzheimer's Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels

Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.

CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.

Sex Differences in Cognition Across Aging

Lee BH, Richard JE, de Leon RG, Yagi S, Galea LAM.

Curr Top Behav Neurosci. 2023;62:235-284. doi: 10.1007/7854_2022_309.

Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review

Grover S, Jain S.

Curr Rev Clin Exp Pharmacol. 2023;18(3):255-269. doi: 10.2174/2772432817666220425121323.

Berberine: Is it a Promising Agent for Mental Disorders Treatment?

Shayganfard M.

Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.

Pathophysiology Associated with Diabetes-induced Tauopathy and Development of Alzheimer's Disease

Sarkar P, Banu S, Bhattacharya S, Bala A, Sur D.

Curr Diabetes Rev. 2023;19(5):e130522204763. doi: 10.2174/1573399818666220513142030.

The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease

Ravikumar M, Mohan S, Velpandian C.

Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.

Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease

Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.

Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.

Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer's Disease

Monsalvo-Maraver LÁ, Maya-López M, Rangel-López E, Túnez I, Tinkov AA, Skalny A, Ferrer B, Aschner M, Santamaría A.

CNS Neurol Disord Drug Targets. 2023;22(7):1039-1056. doi: 10.2174/1871527321666220616094036.

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

de Souza MM, Cenci AR, Teixeira KF, Machado V, Mendes Schuler MCG, Gonçalves AE, Paula Dalmagro A, André Cazarin C, Gomes Ferreira LL, de Oliveira AS, Andricopulo AD.

Curr Med Chem. 2023;30(6):669-688. doi: 10.2174/0929867329666220620162018.

Multicenter and Multichannel Pooling GCN for Early AD Diagnosis Based on Dual-Modality Fused Brain Network

Song X, Zhou F, Frangi AF, Cao J, Xiao X, Lei Y, Wang T, Lei B.

IEEE Trans Med Imaging. 2023 Feb;42(2):354-367. doi: 10.1109/TMI.2022.3187141. Epub 2023 Feb 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias